Black Rock Inc. Salarius Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.16 - $0.42 $18,028 - $47,325	-112,680 Reduced 98.95%	1,197 $0
Q1 2022 May 12, 2022	SELL	$0.34 - $0.54 $1,860 - $2,954	-5,472 Reduced 4.58%	113,877 $45,000
Q4 2021 Feb 10, 2022	BUY	$0.49 - $1.01 $1,489 - $3,070	3,040 Added 2.61%	119,349 $59,000
Q3 2021 Nov 09, 2021	SELL	$0.8 - $1.15 $14,755 - $21,210	-18,444 Reduced 13.69%	116,309 $119,000
Q2 2021 Aug 11, 2021	BUY	$1.02 - $1.52 $137,448 - $204,824	134,753 New	134,753 $142,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $5.1M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.